Log In
BCIQ
Print this Print this
 

GM102 (formerly 3C23K)

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
Description mAb targeting anti-Mullerian hormone receptor type II (AMHR2)
Molecular Target Anti-Mullerian hormone receptor type II (AMHR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer
Regulatory Designation
PartnerGamaMabs Pharma S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/16/2014

Undisclosed

Undisclosed

Undisclosed

10/07/2013

Undisclosed

0

0

Get a free BioCentury trial today